Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Repligen Corporation - Common Stock (NQ:RGEN)

120.70 -3.86 (-3.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Repligen Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Earnings Scheduled For May 4, 2021
Companies Reporting Before The Bell • Lancaster Colony (NASDAQ:LANC) is likely to report quarterly earnings at $1.24 per share on revenue of $340.02 million. •... 
Via Benzinga
Cancer Therapy Novocure Stock Flashes Renewed Technical Strength
Novocure stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 67 to 92. 
Via Investor's Business Daily
10 Biggest Price Target Changes For Monday
Canaccord Genuity raised the price target on Tesla, Inc. (NASDAQ: TSLA) from $419 to $1071. Tesla shares rose 1.5% to $687.13 in pre-market trading. Keybanc lowered the price... 
Via Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Repligen Stock Gets Relative Strength Rating Upgrade With Earnings Due
A Relative Strength Rating upgrade for Repligen shows improving technical performance. Will it continue? 
Via Investor's Business Daily
Medical Device Maker Quanterix Sees Relative Strength Rating Rise To 86
On Tuesday, Quanterix stock hit an important technical milestone, with its Relative Strength (RS) Rating rising into to 86, up from 80 the day before. 
Via Investor's Business Daily
Align Technology Nears Buy Point With Earnings Due
Align Technology is near a possible buy zone ahead of its next quarterly earnings report, expected on or around April 28. 
Via Investor's Business Daily
Cancer Therapy Novocure Stock Still On A High As It Clears Technical Benchmark
Cancer therapy Novocure stock had its Relative Strength (RS) Rating upgraded from 90 to 93 Wednesday. It's also an IBD 50 member. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.